CAR-T cell therapies targeting IL-13Rα2, EGFRvIII and HER2 (ErbB2) have been explored in patients suffering from recurrent glioblastoma and resulted in acceptable safety with some signs of clinical activity [13–15]. Here, ERBB2 is linked to glioblastoma.